Smart Money Alert

Biocon Limited

New PositionBlock Deal

BIOCONPharmaceuticalsMarket Cap₹60K Cr

Value

₹25.04 Cr

6,26,000

Price

₹400

Goldman Sachs

Foreign Investor

The move

Goldman Sachs, an FPI, bought 6,26,000 shares of Biocon Limited for ₹25.04 Cr at ₹400.00 apiece in a block deal.

About Biocon Limited

Visit stock

A leading biotechnology company engaged in the manufacture of innovative pharmaceutical products and research services across multiple therapeutic areas. Biocon specializes in biologics, biosimilars, and small molecule drugs, serving patients in oncology, immunology, and diabetes therapeutics globally. The company operates integrated manufacturing facilities and maintains a strong commitment to developing affordable healthcare solutions for patients in emerging markets worldwide.

About Goldman Sachs

Visit investor

US-based global investment bank (USD 1.6 trillion in assets, USD 3 trillion+ in client AUM through Goldman Sachs Asset Management). India FPI activity covers proprietary, market-making, client flows and active asset management mandates in listed Indian equities.

Get the next move the moment it happens.

Follow Goldman Sachs and Biocon Limited on WhaleWatch, alongside 300+ top investors, funds and FPIs. The newest moves are waiting for you inside.

Explore

Biocon Limited shareholders Goldman Sachs's portfolio All investors All stocks

🤖 We track their every move, post, interview and article. Obsessively.

⚡ Every move reaches your feed in minutes, while it still carries an edge

📊 Stake changes, bulk deals and insider trades, all tracked in one place

📰 A two-minute morning brief, so you start the day already ahead

More moves in Biocon Limited

Kotak Mutual FundIncreased

Kotak Mutual Fund bought 12,77,000 shares of Biocon Limited for ₹49.16 Cr at ₹385.00 apiece in a block deal.

9 Sept 2026